Embecta has hired advisers as it considers a potential sale, the Financial Times reported late Friday. The Parsippany, N.J.-based company makes insulin syringes and pen needles for managing diabetes and is developing an insulin patch-pump for people with Type 2 diabetes. It spun out of BD in 2022 and is still working to transition away from its parent company’s systems. Citing two unnamed sources, the Financial Times reported that Embecta could be an attractive target for private equity because of its low market value and similarities to other companies that have attracted interest from buyers.
Read the full article: Diabetes Device Firm Embecta Considers Sale: Financial Times //
Source: https://www.medtechdive.com/news/embecta-sale-diabetes-private-equity/721996